Survival experience of the population needing hospital treatment for asthma or COPD at the age of 50–54 years  by Jolobe, O.M.P.
RESPIRATORY MEDICINE (1998) 92, 1256-1257 
Letters to the Editor 
Dear Editor 
Survival experience of the population 
needing hospital treatment for asthma or 
COPD at the age of 5 O-54 years 
The 26.7% prevalence of coronary heart disease (CHD) as a 
cause of death in male patients with chronic obstructive 
pulmonary disease (COPD) (1) calls for more vigilance in 
identifying modifiable sequelae of CHD such as left ven- 
tricular systolic dysfunction (LVSD), even in its asympto- 
matic phase, either to prevent decline into the clinically 
overt phase, through the use of angiotensin-converting 
enzyme inhibitors (2), or to reverse the deterioration in left 
ventricular ejection fraction (LVEF), through the use of 
these agents (3). All too often, as reported below, these 
therapeutic opportunities are missed after first presentation 
with COPD, even though the risk factors for COPD are the 
same as those for CHD, and subsequent clinical encounters 
occur when the deterioration in LVEF is already so severe 
as to place the patient in the risk group for sudden 
arrhythmogenic death (4), the latter being also potentially 
preventable through the use of angiotensin-converting 
enzyme inhibitors (5). 
Case Report 
In 1992, then aged 72, this cigarette-smoking man with 
COPD had a documented 1 s forced expiratory volume 
(FEV,) of 0.73 1, forced vital capacity (FVC), 1.97 1, total 
lung capacity (TLC) 102% predicted (102% P), ratio of 
residual volume/total lung capacity (RV/TLC) 64.6%. In 
1998, he was admitted with left ventricular failure (LVF), 
characterized by chest radiography showing pulmonary 
congestion and right basal pleural effusion, and isotope 
ventricular ventriculography showing a LVEF of 16%. 
Comment 
This patient was one of 15, aged 73-91 years, with COPD 
co-existing with LVEF ~40% that I have identified since 
1996. COPD was characterized by TLC > 100% predicted in 
14 cases, the exceptional TLC of 92% P being a feature in a 
76-year-old man with pulmonary congestion and interstitial 
oedema (giving rise to a restrictive pulmonary defect) in 
spite of co-existing bullous emphysema, the latter having 
been previously documented by computerized axial 
tomography 3 yr previously during a series of investigations 
to rule out pneumothorax, the latter simulated by appear- 
ances on chest radiography. Twelve of the fifteen had 
FEV,/ FVC ratio ~60%. Two of the three with FEV,/FVC 
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ratio >60%, namely 62% and 70%, respectively, had co- 
incidental cryptogenic fibrosing alveolitis co-existing with 
COPD (as well as LVSD). The third patient, an 81-year-old 
woman with FEV,/FVC of 65% (and TLC 132% P) had 
been admitted with acute left ventricular failure 6 days 
previously. 
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Careful consideration needed with diag- 
noses of heart disease in COPD patients 
Our own discharge register investigations offer only limited 
possibilities for analysing the significance of cardiac insuf- 
ficiency. Right ventricular insufficiency and car pulmonale 
are recognized as complications of serious COPD for which 
no effective medication is known, but left ventricular sys- 
tolic dysfunction is less commonly thought of as being 
associated with COPD. The latter is a frequently occurring 
problem in clinical work, however, especially at the exacer- 
bation stage of COPD, as Dr Jolobe demonstrates in his 
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